Floatz logo

Egfrt/19-28Z/Il-12 Car T-Lymphocytes

Follicular Lymphoma

Roswell Park Cancer InstituteCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

209 Active assets in the Follicular Lymphoma cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2/3BBB
Romidepsin
City of Hope Medical Center
Phase 2BBB
Irinotecan
University of Michigan Rogel Cancer Center
Phase 2BBB
Recombinant Human Hyaluronidase
National Cancer Institute (NCI)
Phase 3BBB
Busulphan
Masonic Cancer Center, University of Minnesota
Phase 2/3BBB

View all 50 →

Same molecule, other indications

Egfrt/19-28Z/Il-12 Car T-Lymphocytes is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
CC
Indicative ·
43 / 100
View asset →
acute lymphoblastic leukemiaDormant
CC
Indicative ·
43 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →